Medlab Clinical Ltd's (ASX:MDC) Sean Hall tells Proactive that the company is building a cannabis-based drug that is the size of a nanoparticle.
Medlab Clinical and QUT are conducting a clinical trial to assess NRGBioticTM in the management of depression. The clinical trial follows on from two pilot studies which produced significant results of positive clinical benefits to patients administered magnesium orotate and NRGBioticTM respectively.
Medlab Clinical Ltd (MDC) CEO & Managing Director, Sean Hall speaks with Tom Piotrowski about the company’s nutraceuticals sales and its cannabis clinical trial that’s currently underway.
Featured on SkyNews Business Live on the 4th of January 2018
We are proud to announce Medlab's NRGBioticTM is a finalist for the NutraIngredient Awards 2017 - Readers' Food Supplement of the Year! NRGBioticTM is a valuable addition to many Practitioners 'toolbox' and is equally loved by those that use the product. The current clinical research outcomes have provided a novel adjunct option for those with Depression. Seek advice from your healthcare Practitioner. Find out more about NRGBiotic:
Featured on Channel Nine News on the 9th of March 2017
Medlab Clinical is at the forefront of research into obesity and the prevention of diabetes. Medlab's probiotic formulation is currently undergoing clinical trial evaluation in collaboration with the University of Sydney's Boden Institute as featured in a recent Channel 9 news item.